埃克替尼治疗33例晚期非小细胞肺癌的临床分析

目的：探讨埃克替尼治疗33例非小细胞肺癌（ non small cell lung cancer，NSCLC ）患者的疗效及安全性。方法对33例患者的临床特点、治疗效果、不良反应及生存时间进行了回顾性分析。所有患者均口服埃克替尼125 mg，3次/d，直到病变进展或不能耐受。结果 KPS评分升高率为21．2％（7例），埃克替尼总有效率24．2％，疾病控制率87．9％。中位生存时间10．2个月，1年生存率42．4％。脑转移患者的有效率明显高于无脑转移的患者。腺癌、无脑转移、KPS评分高的患者的生存时间优于其他病理类型、有脑转移、KPS评分低的患者。埃克替尼的不良反应主要表现为轻度皮疹、皮肤干燥、腹泻。结论埃克替尼治疗晚期NSCLC具有较好的疗效及安全性。

Clinical analysis of Icotinib in thirty-three advanced NSCLC patients

Objective To evaluate the clinical efficacy and tolerability of Icotinib in advanced NSCLC patients .Methods The clinical characteristics , response to treatment , adverse reaction and survival were retrospectively reviewed in thirty -three advanced NSCLC patients .All these patients received Icotinib 125 mg three times a day until disease progression or unacceptable toxicity .Results Seven cases （21.2%） had improved KPS score .Overall response rate and disease control rate （DCR） of Icotinib were 24.2%and 87.9%, respectively.The median survival time was 10.2 months.One year sur-vival rate was 42.4%.The response rate to Icotinib was significantly higher in patients with brain metastasis than patients without brain metastasis .The overall survival times were significantly longer in patients of adenocarcinoma , without brain metastasis and high KPS score than patients of other pathological type , with brain metastasis and low KPS score .Rash, di-arrhea and xerosis cutis were the most common adverse effects （ AEs） , but usually were mild .Conclusion Icotinib has bet-ter curative effect and insignificant adverse reaction in the treatment of NSCLC .